GleamWall
中文EN

TRDA Entrada Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1689375 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.5%
TTM net income YoY-56.0%
TTM EPS YoY-49.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,303.8%
Net margin-4,058.0%
FCF margin-3,428.1%
EBITDA margin-4,223.6%

Returns

ROE-59.9%
ROA-47.5%
ROIC (approx.)-82.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets25.7%
Debt / equity0.00x
Current ratio7.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$905,000$898,000$875,000$1.30M$1.61M$1.95M$20.56M$37.40M
R&D expense$32.37M$35.37M$33.05M$33.96M$38.36M$37.88M$32.07M$33.41M
SG&A expense$10.22M$10.49M$10.12M$9.55M$10.30M$10.92M$10.27M$9.86M
Operating income-$41.69M-$44.96M-$42.30M-$42.21M-$47.05M-$46.85M-$21.79M-$5.87M
Income tax$27,000$35,000$38,000$92,000$654,000$178,000$0-$1.87M
Net income-$39.74M-$42.76M-$39.72M-$39.16M-$44.13M-$43.10M-$17.35M$1.13M
EBITDA-$40.99M-$44.16M-$41.50M-$41.32M-$45.85M-$45.75M-$20.84M-$4.88M
EPS (basic)-0.94-1.01-0.95—-1.06-1.04-0.42—
EPS (diluted)-0.94-1.01-0.95—-1.06-1.04-0.42—
Weighted avg. shares (diluted)42.37M42.22M41.84M—41.46M41.34M41.07M—
Balance sheet
Cash & equivalents$112.24M$99.28M$76.44M$90.39M$97.24M$76.43M$71.79M$105.16M
Current assets$202.95M$232.70M$266.87M$306.25M$338.26M$369.15M$403.19M$440.04M
PP&E, net$5.21M$5.72M$6.51M$7.31M$8.41M$9.81M$10.67M$10.93M
Total assets$266.88M$298.88M$335.52M$377.38M$412.90M$448.78M$486.48M$526.32M
Current liabilities$25.86M$21.37M$19.20M$24.45M$24.02M$19.80M$18.43M$39.48M
Total liabilities$68.56M$65.47M$64.66M$71.25M$72.18M$69.28M$69.22M$97.64M
Shareholders' equity$198.32M$233.41M$270.85M$306.13M$340.72M$379.50M$417.26M$428.68M
Shares outstanding39.15M38.94M38.82M38.28M38.22M38.03M37.94M37.57M
Cash flow statement
Operating cash flow-$29.96M-$32.46M-$41.70M-$32.20M-$28.31M-$29.49M-$38.51M-$31.61M
Capital expenditure$161,000$11,000$44,000-$207,000-$171,000$275,000$1.14M$635,000
Free cash flow-$30.12M-$32.47M-$41.74M-$32.00M-$28.14M-$29.76M-$39.65M-$32.24M
Investing cash flow$42.92M$54.95M$26.99M$29.12M$49.11M$33.80M$4.78M$53.37M
Financing cash flow$0$350,000$100,000$192,000$8,000$337,000$350,000$1.40M
Depreciation & amortization$700,000$800,000$805,000$886,000$1.20M$1.10M$946,000$992,000
Stock-based compensation$4.78M$5.15M$4.74M$4.36M$5.12M$5.05M$5.09M$4.70M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.